Therefore, potential HMGCS1 inhibitors can be explored for the treatment of cancers including CSN6‐overexpressing HCC, such as Gypenosides[23] and ligustilide.[24] It will be an exciting avenue for using these inhibitors in cancer prevention or therapy; for examples, in HCC patients when CSN6/HMGCS1 expression was prognostically detrimental. This evidence concerns the gene COPS6 and hepatocellular carcinoma.